M2 TAMs produce IL-10 at the tumor site leading to resistance of breast cancer to paclitaxel treatment (Yang et al., 2015) and this resistance can be abrogated with the administration of an IL-10 neutralizing antibody (Yang et al., 2015) (Figure 4). Here, IL10 is linked to breast cancer.